NasdaqGS:NVAXBiotechs
The Bull Case For Novavax (NVAX) Could Change Following EU Vaccine Transfer Deal With Sanofi
On October 7, Novavax completed the transfer of its COVID-19 vaccine, Nuvaxovid, to Sanofi, granting Sanofi full commercial and regulatory responsibility for the product in the EU under a partnership that could bring Novavax up to US$450 million in milestone payments.
This agreement with Sanofi marks a significant change in Novavax’s business model, potentially reducing operational costs while creating new sources of recurring revenue through partnership milestones.
We’ll examine how the...